AI Article Synopsis
- Acetaminophen (APAP) is commonly used for pain relief but can cause liver failure in toxic doses; this study examines its effects at lower doses on IGF-1 levels in rats.
- Both low (100 mg/kg) and high (250 mg/kg) doses of APAP resulted in reduced liver and blood IGF-1 levels compared to controls, with no significant difference in liver IGF-1 between the two doses, but a notable difference in blood levels.
- Histological analysis indicated mild structural changes at low doses and severe damage at high doses, suggesting that blood IGF-1 levels may help assess liver damage from therapeutic APAP use.
Article Abstract
Acetaminophen (APAP) is widely used in the treatment of pain. Toxic doses of APAP cause acute liver failure, but therapeutic doses are believed to be safe. The purpose of this study is to investigate the effects of administration of subtoxic doses of APAP on liver and blood levels of insulin-like growth factor-1 (IGF-1) in rats. Low dose (100 mg/kg) and high dose (250 mg/kg) of APAP were intraperitoneally injected into Wistar albino rats. Following administration of therapeutic doses of APAP, there were no significant changes in serum transaminases and liver glutathione levels. Both doses of APAP induced a decrease in liver and blood levels of IGF-1 when compared with the controls. There was no significant difference in liver IGF-1 levels between the high-dose and low-dose APAP groups; however, there was a significant difference in blood IGF-1 levels between both the groups. The histological examination showed that low dose of APAP induced mild degree of structural change, while high dose of APAP induced severe structural damage. In conclusion, these results suggest that blood IGF-1 levels may have a value in predicting hepatic damage resulting from therapeutic doses of APAP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0748233713498439 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Examining the Impact of Diet-and-Exercise-Induced Weight Loss on Drug Metabolism and Gastric Emptying in Patients with Obesity.
J Clin Pharmacol
January 2025
Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Obesity significantly influences drug pharmacokinetics (PK), which challenges optimal dosing. This study examines the effects of diet-and-exercise-induced weight loss on key drug-metabolizing enzymes and gastric emptying in patients with obesity, who frequently require medications for comorbidities. Participants followed a structured weight management program promoting weight loss over 3-6 months and were not concomitantly on potential CYP inducers or inhibitors.
View Article and Find Full Text PDFExparel and Outpatient Alveolar Bone Grafting: A Feasibility Study.
Cleft Palate Craniofac J
January 2025
Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY, USA.
Objectives: To examine the feasibility of outpatient alveolar bone grafting (ABG) using Exparel (bupivacaine liposome injectable suspension) for donor site analgesia.
Design: Retrospective, observational study.
Setting: Single institution, 39-month retrospective review.
How Much Pain Medication Do Patients Require After Posterior Iliac Crest Bone Graft to the Alveolar Cleft?
Cleft Palate Craniofac J
January 2025
Plastic and Oral Surgery, Boston Children's Hospital, Boston, Massachusetts, USA.
Objective: The purpose of this study was to quantify analgesic use following alveolar cleft bone grafting (ABG) utilizing a posterior iliac crest (PIC) donor site.
Design: This is a prospective cohort study of consecutive patients that underwent ABG with PIC in a 10 month period from November 2022 to September 2023.
Setting: Tertiary care free-standing pediatric hospital.
Urinary Acetaminophen Metabolites and Clinical Outcomes in Extremely Premature Infants.
Am J Perinatol
January 2025
Pediatrics, University of California San Francisco, San Francisco, United States.
Objective: Extremely premature infants are treated with acetaminophen (APAP) for pain and patent ductus arteriosus. High doses of APAP in adults are toxic, and a recent study found an association between APAP metabolite levels in mothers' breast milk and both bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) in their premature infants. In this study, we determined levels of APAP metabolites in urine of infants at high risk for BPD and ROP.
View Article and Find Full Text PDFThe Utilization of Acetaminophen for Managing PGE1-Induced Fever in Neonates with Critical Congenital Heart Disease.
Children (Basel)
December 2024
Department of Neonatology, SBU. Dr. Sami Ulus Maternity and Child Research and Training Hospital, Babur St., Number: 36, Altındag 06080, Turkey.
Introduction: We aimed to retrospectively evaluate the use of acetaminophen, which may be a risk factor for the ductal canal, in the treatment of fever due to prostaglandin E1 (PGE1) infusion in newborns with critical congenital heart disease (CCHD).
Methods: The study included newborns who were followed-up in our neonatal intensive care unit with the diagnosis of critical congenital heart disease, developed fever due to PGE1 infusion and had acetaminophen administered for antipyretic treatment. The patent ductus arteriosus diameters of the patients were evaluated by echocardiographic imaging before intravenous acetaminophen treatment and at the end of the day of acetaminophen treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!